Erratum: Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and phase 2 trials (Neurology (2016) 87 (392-400) DOI: 10.1212/WNL.0000000000002889);Transplantation of spinal cord-derived neural stem cells for ALS: Analysis of phase 1 and 2 trials

Neurology

Volumn 87, Issue 4, 2016, Pages 392-400

  Glass, Jonathan D ^a   Hertzberg, Vicki S ^b   Boulis, Nicholas M ^a   Riley, Jonathan ^a   Federici, Thais ^a   Polak, Meraida ^a   Bordeau, Jane ^a   Fournier, Christina ^a   Johe, Karl ^c   Hazel, Tom ^c   Cudkowicz, Merit ^d   Atassi, Nazem ^d   Borges, Lawrence F ^e   Rutkove, Seward B ^f   Duell, Jayna ^g   Patil, Parag G ^g   Goutman, Stephen A ^g   Feldman, Eva L ^g  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c Neuralstem Inc   (United States)

^d Neurological Clinical Research Institute   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^g UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; AMYOTROPHIC LATERAL SCLEROSIS FUNCTIONAL RATING SCALE REVISED; ARTICLE; ASSESSMENT OF HUMANS; CERVICAL SPINAL CORD; CLINICAL ARTICLE; CONTROLLED STUDY; DETERIORATION; DIARRHEA; DISEASE COURSE; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LABORATORY; LUMBAR SPINAL CORD; MALE; MENTAL DISEASE; METABOLIC DISORDER; MIDDLE AGED; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEURAL STEM CELL; NEUROLOGIC DISEASE; OPEN STUDY; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PAIN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RATING SCALE; RESPIRATORY TRACT DISEASE; SKIN DISEASE; SPINAL CORD; STEM CELL TRANSPLANTATION; SURGEON; TREATMENT OUTCOME; UROGENITAL TRACT DISEASE; VASCULAR DISEASE; ADVERSE EFFECTS; CERVICAL VERTEBRA; CLINICAL TRIAL; LUMBOSACRAL REGION; ONSET AGE; PROCEDURES; SURGERY; TRANSPLANTATION;

ADULT; AGE OF ONSET; AMYOTROPHIC LATERAL SCLEROSIS; CERVICAL VERTEBRAE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUMBOSACRAL REGION; MALE; MIDDLE AGED; NEURAL STEM CELLS; SPINAL CORD; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 84980395560     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000004316     Document Type: Erratum

References (20)

1. Xu L, Shen P, Hazel T, Johe K, Koliatsos VE. Dual transplantation of human neural stem cells into cervical and lumbar cord ameliorates motor neuron disease in SOD1 transgenic rats. Neurosci Lett 2011;494:222-226
2. Xu L, Yan J, Chen D, et al. Human neural stem cell grafts ameliorate motor neuron disease in SOD-1 transgenic rats. Transplantation 2006;82:865-875
3. Yan J, Xu L, Welsh AM, et al. Combined immunosuppressive agents or CD4 antibodies prolong survival of human neural stem cell grafts and improve disease outcomes in amyotrophic lateral sclerosis transgenic mice. Stem Cells 2006;24:1976-1985
4. Yan J, Xu L, Welsh AM, et al. Extensive neuronal differentiation of human neural stem cell grafts in adult rat spinal cord. PLoS Med 2007;4:e39
5. Glass JD, Boulis NM, Johe K, et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells 2012;30:1144-1151
6. Feldman EL, Boulis NM, Hur J, et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol 2014;75:363-373
7. Riley J, Butler J, Baker KB, et al. Targeted spinal cord therapeutics delivery: stabilized platform and microelectrode recording guidance validation. Stereotact Funct Neurosurg 2008;86:67-74
8. Raore B, Federici T, Taub J, et al. Cervical multilevel intraspinal stem cell therapy: assessment of surgical risks in Gottingen minipigs. Spine 2011;36:E164-E171
9. Riley J, Federici T, Polak M, et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes. Neurosurgery 2012;71:405-416; discussion 416
10. Riley J, Glass J, Feldman EL, et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I trial, cervical microinjection, and final surgical safety outcomes. Neurosurgery 2014;74:77-87
11. Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci 2008;275: 69-73
12. Cudkowicz ME, Titus S, Kearney M, et al. Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13:1083-1091
13. Atassi N, Berry J, Shui A, et al. The PRO-ACT database: design, initial analyses, and predictive features. Neurology 2014;83:1719-1725
14. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer; 2000
15. Elman LB, Siderowf A, Houseman G, Kelley M, McCluskey LF. Venous thrombosis in an ALS population over four years. Amyotroph Lateral Scler Other Mot Neuron Disord 2005;6:246-249
16. Tominaga H, Setoguchi T, Tanabe F, et al. Risk factors for venous thromboembolism after spine surgery. Medicine 2015;94:e466
17. Qureshi M, Schoenfeld DA, Paliwal Y, Shui A, Cudkowicz ME. The natural history of ALS is changing: improved survival. Amyotroph Lateral Scler 2009;10: 324-331
18. Cudkowicz ME, Katz J, Moore DH, et al. Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11:259-265
19. Kraemer HC, Mintz J, Noda A, Tinklenberg J, Yesavage JA. Caution regarding the use of pilot studies to guide power calculations for study proposals. Arch Gen Psychiatry 2006;63:484-489
20. Kuffner R, Zach N, Norel R, et al. Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. Nat Biotechnol 2015;33:51-57